AR
Therapeutic Areas
Stoke Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zorevunersen (STK-001) | Dravet Syndrome | Phase 3 |
| STK-002 | Autosomal Dominant Optic Atrophy (ADOA) | Preclinical |
| Undisclosed TANGO ASO | SYNGAP1-Related Intellectual Disability | Discovery |
Leadership Team at Stoke Therapeutics
EM
Edward M. Kaye, M.D.
Chief Executive Officer
IA
Isabel Aznarez, Ph.D.
Founder & Former Head of Discovery
BT
Barry Ticho, M.D., Ph.D.
Chief Medical Officer
HC
Hugh Cole
Chief Business Officer
SJ
Stephen J. Tulipano, CPA
Chief Financial Officer
AA
Arthur A. Levin, Ph.D.
Executive VP, Platform Biology